0.0001  0 (0%)		05-23 16:00
Open: 0.0002 High: 0.0002 Volume: 222		Pre. Close: 9.9999997E-5 Low: 0.0001 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0	1-year :	0
Resists	First :	0	Second :	0
Pivot price	0
Supports	First :	0	Second :	0
MAs	MA(5) :	0	MA(20) :	0
	MA(100) :	0	MA(250) :	0
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	0	D(3) :	0
RSI	RSI(14): 0.4
52-week	High :	0.03	Low :	0

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CMRA ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0 - 0	0 - 0
Low:	0 - 0	0 - 0
Close:	0 - 0	0 - 0

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

Thu, 04 Jan 2024
Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option - GlobeNewswire

Sat, 26 Aug 2023
These Are the ONLY 7 Penny Stocks to Consider in August 2023 - Nasdaq

Thu, 10 Aug 2023
Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights - citybiz

Wed, 09 Nov 2022
Comera Life Sciences Appoints Janice Marie McCourt as Chief Business Officer - citybiz

Sun, 19 Jun 2022
US stock market gainers for third week in June - Nairametrics

Wed, 15 Jun 2022
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.50% - Investing.com India

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	-3 (M)
Shares Float	0 (M)
Held by Insiders	3.074e+007 (%)
Held by Institutions	8.56e+006 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.22
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	582.4 %
Return on Equity (ttm)	-119.4 %
Qtrly Rev. Growth	629 %
Gross Profit (p.s.)	95.58
Sales Per Share	187.12
EBITDA (p.s.)	352258
Qtrly Earnings Growth	-7.55e+006 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	-0.01
Price to Sales	0
Price to Cash Flow	0

Dividend	281550
Forward Dividend	27930
Dividend Yield	281550000000%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.